F-1/A: Evaxion Biotech Seeks $10.85 Million in New Offering to Advance AI-Driven Vaccine Pipeline

Evaxion Biotech A/S is conducting a best-efforts offering to raise up to $10.85 million through the sale of American Depositary Shares and warrants to fund its clinical and preclinical programs.

Summary

• Evaxion Biotech A/S is offering up to 7,640,845 American Depositary Shares (ADSs) and accompanying warrants, or pre-funded warrants in lieu of ADSs, to raise capital.
• The offering is on a best-efforts basis, meaning there is no guarantee that all securities will be sold.
• The assumed public offering price is $1.42 per ADS and accompanying warrant, but the actual price will be determined through negotiations.
• The company is also offering pre-funded warrants to certain purchasers who would otherwise exceed beneficial ownership limits.
• The offering is set to terminate on January 31, 2025, unless terminated earlier by the company.
• The company intends to use the net proceeds to advance its preclinical and clinical pipeline and for general operating expenses.
• Evaxion is a clinical-stage TechBio company focused on AI-driven vaccine development for cancer and infectious diseases.
• The company's AI-Immunology platform consists of five proprietary AI prediction models.
• Evaxion has a three-pronged business model focusing on vaccine target discovery collaborations, advancing its proprietary pipeline, and developing responder models.
• The company has a significantly expanded partnership with MSD, including potential milestones of $592 million per product.
• Evaxion's cash and cash equivalents were $4.6 million as of September 30, 2024, not including $3.2 million upfront from the MSD agreement received in October 2024.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The company has promising technology and partnerships, but faces financial challenges and risks associated with clinical development and market competition. The delisting notice is a significant negative factor.

Positives

• The company has a strong AI-Immunology platform with five proprietary AI prediction models.
• Evaxion has a three-pronged business model focusing on vaccine target discovery collaborations, advancing its proprietary pipeline, and developing responder models.
• The company has a significantly expanded partnership with MSD, including potential milestones of $592 million per product.
• The company has a clinical-stage cancer pipeline of novel personalized therapeutic vaccines.
• The company has a preclinical prophylactic vaccine pipeline for bacterial and viral diseases.
• The company has demonstrated a correlation between the predictive power of AI and clinical response in patients.
• The company's AI-Immunology platform offers the potential to expand partnerships and product candidate portfolio.
• The company has in-house capabilities for experimental screening and testing of novel targets/product leads.
• The company has established a direct link between the predictive power of its AI-Immunology platform and preclinical and clinical outcome.

Negatives

• The offering is on a best-efforts basis, meaning there is no guarantee that all securities will be sold.
• The company has incurred significant losses since its inception and anticipates continuing to incur losses.
• The company will require substantial additional financing to achieve its goals.
• The company is a clinical-stage company with only two product candidates in early clinical trials.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• The company's business model is based upon partnering, and there is no guarantee that it will be able to secure needed partnerships.
• The company may encounter difficulties in manufacturing to supply clinical studies and the market.
• The company may be involved in lawsuits to protect or enforce its intellectual property.
• The company received a delisting notice from Nasdaq Capital Markets, which it has appealed.

Risks

• The company may not be able to regain compliance with Nasdaq listing requirements.
• The company has incurred significant losses since its inception and anticipates continuing to incur losses.
• The company will require substantial additional financing to achieve its goals.
• The company is a clinical-stage company with only two product candidates in early clinical trials.
• The company faces significant competition in the biotechnology and pharmaceutical industries.
• The company's business model is based upon partnering, and there is no guarantee that it will be able to secure needed partnerships.
• The company may encounter difficulties in manufacturing to supply clinical studies and the market.
• The company may be involved in lawsuits to protect or enforce its intellectual property.
• The company's product candidates may not work as intended or may cause undesirable side effects.
• The company relies on third parties for manufacturing and clinical trials.
• The company may encounter difficulties in enrolling patients in clinical trials.

Future Outlook

The company plans to continue its multi-partner approach to value realization, advance the EVX-01 phase 2 trial, strengthen its AI-Immunology platform, and progress its ERV-based precision vaccine concept towards clinical development. The company also aims to advance existing partnerships, including bringing the MSD collaboration to option exercise.

Management Comments

• The company is excited about the commercial potential of EVX-01.
• The company is thrilled about the interest it is seeing from potential partners in both the establishment of new vaccine discovery and development collaborations as well as in its existing pipeline assets.
• The company is excited about its significantly expanded vaccine collaboration with MSD and the financial and strategic value it brings.

Industry Context

The document highlights the growing market for vaccines, particularly in the areas of cancer and infectious diseases, and the increasing importance of AI in drug discovery and development. The company's focus on personalized and precision medicine aligns with current industry trends.

Comparison to Industry Standards

• The company claims its AI-Immunology platform offers 90%+ cheaper target discovery compared to reverse vaccinology and requires 80% fewer targets to be tested.
• The company's EVX-01 Phase 1 trial demonstrated a 67% overall response rate in metastatic melanoma patients, compared to a historical 40% with anti-PD-1 treatment alone.
• The company's EVX-01 Phase 2 one-year clinical data demonstrated a 69% Overall Response Rate, reduction in tumor target lesions in 15 out of 16 patients, an immunogenicity rate of 79%, and a positive correlation between AI-Immunology platform predictions and immune responses.
• The company's EVX-02 Phase 1/2a trial showed that all 10 patients who received the full dosing schedule were relapse-free at their last assessment.
• The company's RAVEN model identified 15 out of 17 T-cell epitopes that induced T-cell activation and provided significant protection against lethal SARS-CoV-2 challenge in a mouse model.
• The company's EDEN model identified novel vaccine antigens for seven bacteria pathogens, demonstrating protection in pre-clinical mouse infection models.

Management Changes

Legal Proceedings

• In April 2022, SSI initiated a legal proceeding against the company claiming sole ownership of a patent application. The lawsuit was lifted in June 2024 on a walk-away basis with no compensation by Evaxion to SSI.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial situation and the nature of the offering.
• Employees may be affected by the company's financial challenges and potential restructuring.
• Customers and partners may be impacted by the company's ability to deliver on its commitments.
• Creditors may be at risk due to the company's financial instability.

Next Steps

• The company will continue to advance its preclinical and clinical pipeline.
• The company will continue to strengthen its AI-Immunology platform.
• The company will progress its ERV-based precision vaccine concept towards clinical development.
• The company will advance existing partnerships, including bringing the MSD collaboration to option exercise.

Key Dates

Keywords

AI-Immunology, vaccine, cancer, infectious disease, American Depositary Shares, warrants, pre-funded warrants, clinical trials, biotechnology, drug development, MSD, partnership, neoantigen, ERV, AI, immunotherapy